Trials / Completed
CompletedNCT04014777
Study of NGM621 in Participants With Geographic Atrophy
A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM621 | NGM621 Dose 1 |
| BIOLOGICAL | NGM621 | NGM621 Dose 2 |
| BIOLOGICAL | NGM621 | NGM621 Dose 3 |
| BIOLOGICAL | NGM621 | NGM621 Dose 4 |
Timeline
- Start date
- 2019-07-26
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
- First posted
- 2019-07-10
- Last updated
- 2020-10-01
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04014777. Inclusion in this directory is not an endorsement.